British Columbia Investment Management Corp Zai Lab LTD Transaction History

British Columbia Investment Management Corp

$16 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$34.2 - $51.69 $20,520 - $31,014	600 Added 1.7%	35,800 $1.22 Million
Q2 2022 Aug 12, 2022	SELL	$23.14 - $49.68 $7,196 - $15,450	-311 Reduced 0.88%	35,200 $1.22 Million
Q1 2022 May 12, 2022	BUY	$27.77 - $64.4 $103,054 - $238,988	3,711 Added 11.67%	35,511 $1.56 Million
Q4 2021 Feb 11, 2022	BUY	$54.9 - $105.21 $16,470 - $31,562	300 Added 0.95%	31,800 $2 Million
Q2 2021 Aug 09, 2021	BUY	$125.11 - $180.0 $200,176 - $288,000	1,600 Added 5.35%	31,500 $5.58 Million
Q1 2021 Apr 30, 2021	BUY	$126.27 - $191.71 $75,762 - $115,026	600 Added 2.05%	29,900 $3.99 Million
Q4 2020 Feb 02, 2021	SELL	$81.94 - $135.34 $73,746 - $121,806	-900 Reduced 2.98%	29,300 $3.97 Million
Q3 2020 Nov 10, 2020	BUY	$73.3 - $89.48 $520,430 - $635,308	7,100 Added 30.74%	30,200 $2.51 Million
Q2 2020 Aug 12, 2020	BUY	$48.82 - $82.53 $302,684 - $511,686	6,200 Added 36.69%	23,100 $1.9 Million
Q1 2020 May 13, 2020	BUY	$39.1 - $62.9 $660,790 - $1.06 Million	16,900 New	16,900 $870,000

Others Institutions Holding ZLAB

# of Institutions

121

Shares Held

46.7M

Call Options Held

223K

Put Options Held

588K

Janus Henderson Group PLC London, X0

8.76M
Shares

$234 Million
0.11% of portfolio
Wellington Management Group LLP Boston, MA

8.44M
Shares

$225 Million
0.04% of portfolio
Capital World Investors Los Angeles, CA

6.44M
Shares

$172 Million
0.02% of portfolio
Viking Global Investors LP

1.95M
Shares

$52.1 Million
0.18% of portfolio
Bamco Inc New York, NY

1.91M
Shares

$50.9 Million
0.13% of portfolio

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.62B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.

Account